Skip to main content
NCBI home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2002 Aug;78(4):255–260. doi: 10.1136/sti.78.4.255

Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999

J Del Amo 1, J Del Romero 1, A Barrasa 1, S Perez-Hoyos 1, C Rodriguez 1, M Diez 1, S Garcia 1, V Soriano 1, J Castilla 1, G the 1
PMCID: PMC1744500  PMID: 12181462

Abstract

Objective: To study HIV progression from seroconversion over a 15 year period and measure the population effectiveness of highly active antiretroviral therapy (HAART).

Methods: A cohort study of people with well documented dates of seroconversion. Cumulative risk of AIDS and death were calculated by extended Kaplan-Meier allowing for late entry. Cox proportional hazards models were used to study variables associated with HIV progression. To assess the impact of HAART, calendar time was divided in three periods; before 1992, 1992–6, and 1997–9.

Results: From January 1985 to May 2000, 226 seroconverters were identified. The median seroconversion interval was 11 months, median seroconversion date was March 1993. 202 (89%) were men, 76% of whom were homo/bisexual. A 66% reduction in progression to AIDS was observed in 1997–9 compared to 1992–96 (HR 0.34 95% CI: 0.16 to 0.70). People with primary education appeared to have faster progression to AIDS compared to those with university studies (HR 2.69 95%CI: 1.17 to 6.16). An 82% reduction in mortality from HIV seroconversion was observed in 1997–9 (HR 0.18 95% CI: 0.05 to 0.68) compared to 1992–6. Progression to death for people with primary education was twice as fast as for those with university education (p 0.0007). People without confirmation of an HIV negative test had faster progression (HR 4.47 95% CI: 1.18 to 16.92).

Conclusions: The reduction in progression to AIDS and death from seroconversion from 1992–6 to 1997–9 in Madrid is likely to be attributable to HAART. HIV progression was faster in subjects with primary education; better educational level may be associated with better adherence to medication.

Full Text

The Full Text of this article is available as a PDF (197.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajdacic-Gross V., Zellweger U., Wang J., Fleerackers Y., Somaini B. How complete is AIDS surveillance in Europe? An eagle eye comparison with mortality data. J Epidemiol Community Health. 2001 Jan;55(1):52–56. doi: 10.1136/jech.55.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barrasa A., Castilla J., Pereira J., Herrera D., Martínez-Navarro F. Exhaustividad de los registros de sida en España. Gac Sanit. 2001 Nov-Dec;15(6):482–489. doi: 10.1016/s0213-9111(01)71610-x. [DOI] [PubMed] [Google Scholar]
  3. Briones C., Pérez-Olmeda M., Rodríguez C., del Romero J., Hertogs K., Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):145–150. doi: 10.1097/00042560-200102010-00006. [DOI] [PubMed] [Google Scholar]
  4. Castilla J., Martínez de Aragón M. V., Gutiérrez A., Llácer A., Belza M. J., Ruiz C., Pérez de la Paz J., Noguer I. Impact of human immunodeficiency virus infection on mortality among young men and women in Spain. Int J Epidemiol. 1997 Dec;26(6):1346–1351. doi: 10.1093/ije/26.6.1346. [DOI] [PubMed] [Google Scholar]
  5. Detels R., Muñoz A., McFarlane G., Kingsley L. A., Margolick J. B., Giorgi J., Schrager L. K., Phair J. P. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998 Nov 4;280(17):1497–1503. doi: 10.1001/jama.280.17.1497. [DOI] [PubMed] [Google Scholar]
  6. Detels R., Tarwater P., Phair J. P., Margolick J., Riddler S. A., Muñoz A., Multicenter AIDS Cohort Study Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001 Feb 16;15(3):347–355. doi: 10.1097/00002030-200102160-00008. [DOI] [PubMed] [Google Scholar]
  7. Dorrucci M., Balducci M., Pezzotti P., Sinicco A., Alberici F., Rezza G. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS). J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):65–70. doi: 10.1097/00042560-199909010-00008. [DOI] [PubMed] [Google Scholar]
  8. Egger M., Hirschel B., Francioli P., Sudre P., Wirz M., Flepp M., Rickenbach M., Malinverni R., Vernazza P., Battegay M. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997 Nov 8;315(7117):1194–1199. doi: 10.1136/bmj.315.7117.1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gordillo V., del Amo J., Soriano V., González-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999 Sep 10;13(13):1763–1769. doi: 10.1097/00002030-199909100-00021. [DOI] [PubMed] [Google Scholar]
  10. Junghans C., Low N., Chan P., Witschi A., Vernazza P., Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS. 1999 Dec 24;13(18):2547–2554. doi: 10.1097/00002030-199912240-00008. [DOI] [PubMed] [Google Scholar]
  11. Katz M. H., Hsu L., Lingo M., Woelffer G., Schwarcz S. K. Impact of socioeconomic status on survival with AIDS. Am J Epidemiol. 1998 Aug 1;148(3):282–291. doi: 10.1093/oxfordjournals.aje.a009637. [DOI] [PubMed] [Google Scholar]
  12. Muñoz A., Gange S. J., Jacobson L. P. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS. 2000 Apr 14;14(6):754–756. doi: 10.1097/00002030-200004140-00020. [DOI] [PubMed] [Google Scholar]
  13. Palella F. J., Jr, Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853–860. doi: 10.1056/NEJM199803263381301. [DOI] [PubMed] [Google Scholar]
  14. Pezzotti P., Galai N., Vlahov D., Rezza G., Lyles C. M., Astemborski J. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):275–282. doi: 10.1097/00042560-199903010-00010. [DOI] [PubMed] [Google Scholar]
  15. Phillips A. N., Grabar S., Tassie J. M., Costagliola D., Lundgren J. D., Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS. 1999 Oct 22;13(15):2075–2082. doi: 10.1097/00002030-199910220-00010. [DOI] [PubMed] [Google Scholar]
  16. Phillips A. N., Lee C. A., Elford J., Webster A., Janossy G., Timms A., Bofill M., Kernoff P. B. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr. 1991;4(10):970–975. [PubMed] [Google Scholar]
  17. Porter K., Johnson A. M., Phillips A. N., Darbyshire J. H. The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters. AIDS. 1999 Oct 1;13(14):1943–1951. doi: 10.1097/00002030-199910010-00018. [DOI] [PubMed] [Google Scholar]
  18. Prins M., Brettle R. P., Robertson J. R., Hernández Aguado I., Broers B., Carré N., Goldberg D. J., Zangerle R., Coutinho R. A., van den Hoek A. Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? Int J Epidemiol. 1999 Jun;28(3):541–549. doi: 10.1093/ije/28.3.541. [DOI] [PubMed] [Google Scholar]
  19. Pérez-Hoyos S., Aviñ M., Hernández I., González J., Ruiz I. Tiempo libre de SIDA y supervivencia de una cohorte de usuarios de drogas por vía parenteral seroconvertores frente al VIH. Gac Sanit. 1999 Sep-Oct;13(5):337–345. doi: 10.1016/s0213-9111(99)71384-1. [DOI] [PubMed] [Google Scholar]
  20. Rapiti E., Porta D., Forastiere F., Fusco D., Perucci C. A. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group. Epidemiology. 2000 Sep;11(5):496–501. doi: 10.1097/00001648-200009000-00003. [DOI] [PubMed] [Google Scholar]
  21. Schechter M. T., Hogg R. S., Aylward B., Craib K. J., Le T. N., Montaner J. S. Higher socioeconomic status is associated with slower progression of HIV infection independent of access to health care. J Clin Epidemiol. 1994 Jan;47(1):59–67. doi: 10.1016/0895-4356(94)90034-5. [DOI] [PubMed] [Google Scholar]
  22. Vanhems P., Hirschel B., Phillips A. N., Cooper D. A., Vizzard J., Brassard J., Perrin L. Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis. 2000 Jun 19;182(1):334–337. doi: 10.1086/315687. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES